• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma.

作者信息

Portuguese Andrew J, Fang Min, Tuazon Sherilyn A, Pont Margot, Qu Xiaoyu, Shasha Carolyn, Comstock Melissa, Lyons Justina, Cole Gabriel, Newell Evan W, Glynn Emily, Soma Lorinda A, Green Damian J

机构信息

Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.

University of Washington, Department of Medicine, Seattle, WA.

出版信息

Blood Adv. 2023 Dec 12;7(23):7235-7238. doi: 10.1182/bloodadvances.2023011295.

DOI:10.1182/bloodadvances.2023011295
PMID:37844282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10698540/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76f4/10698540/74a36cc327d1/BLOODA_ADV-2023-011295-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76f4/10698540/74a36cc327d1/BLOODA_ADV-2023-011295-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76f4/10698540/74a36cc327d1/BLOODA_ADV-2023-011295-gr1.jpg

相似文献

1
Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma.获得性CD38基因缺失作为多发性骨髓瘤中肿瘤抗原逃逸的一种机制。
Blood Adv. 2023 Dec 12;7(23):7235-7238. doi: 10.1182/bloodadvances.2023011295.
2
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.肿瘤抑制因子 miR-26a 通过靶向 CD38 可作为多发性骨髓瘤的新型潜在治疗药物。
Cancer Res. 2020 May 15;80(10):2031-2044. doi: 10.1158/0008-5472.CAN-19-1077. Epub 2020 Mar 19.
3
Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis.抗CD38疗法对具有高危细胞遗传学特征的多发性骨髓瘤的影响：系统评价和荟萃分析。
Leuk Lymphoma. 2020 Oct;61(10):2519-2522. doi: 10.1080/10428194.2020.1772475. Epub 2020 Jun 6.
4
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.基于 CD38 受体表达和功能的抗 CD38 治疗新见解：多发性骨髓瘤模型。
Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.
5
Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials.多发性骨髓瘤中基于靶向CD38抗原单克隆抗体疗法的血液学和感染并发症：一项随机对照试验的荟萃分析
Leuk Res. 2021 Nov;110:106714. doi: 10.1016/j.leukres.2021.106714. Epub 2021 Sep 25.
6
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的CD38嵌合抗原受体工程化T细胞的临床前评估。
Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.
7
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.复发的髓外多发性骨髓瘤中的抗原性漂移：无CD38表达的浆细胞。
Leuk Lymphoma. 2012 Apr;53(4):721-4. doi: 10.3109/10428194.2011.623257. Epub 2011 Nov 25.
8
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.达雷妥尤单抗（抗CD38）可导致红细胞表面CD38缺失。
Blood. 2017 Jun 1;129(22):3033-3037. doi: 10.1182/blood-2016-11-749432. Epub 2017 Apr 3.
9
Double CD38/CD138 negative multiple myeloma.双CD38/CD138阴性多发性骨髓瘤
Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):64-66. doi: 10.1016/j.hemonc.2017.08.003. Epub 2017 Oct 18.
10
[Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Oct;31(5):1574-1578. doi: 10.19746/j.cnki.issn.1009-2137.2023.05.051.

引用本文的文献

1
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.基于基因组和免疫的多发性骨髓瘤复发难治患者对达雷妥尤单抗治疗的耐药决定因素。
Blood Cancer J. 2024 Jul 19;14(1):117. doi: 10.1038/s41408-024-01096-6.

本文引用的文献

1
Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.抗 CD38 单克隆抗体对血液相容性检测的干扰：通过功能表位作图区分伊沙妥昔单抗和达雷妥尤单抗。
Transfusion. 2022 Nov;62(11):2334-2348. doi: 10.1111/trf.17137. Epub 2022 Oct 14.
2
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.达雷妥尤单抗单药治疗经大量预处理的复发或难治性多发性骨髓瘤患者：2期GEN501和SIRIUS试验的最终结果
Lancet Haematol. 2020 Jun;7(6):e447-e455. doi: 10.1016/S2352-3026(20)30081-8.
3
VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
VS38 鉴定出在达雷妥尤单抗治疗后 CD38 弱表达的骨髓瘤细胞和浆细胞，这会干扰 CD38 检测达 4 至 6 个月。
Am J Clin Pathol. 2020 Jan 2;153(2):221-228. doi: 10.1093/ajcp/aqz153.
4
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.对 CD38 靶向单克隆抗体治疗耐药的多发性骨髓瘤患者的结局。
Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.
5
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.达雷妥尤单抗对CD38的长期饱和作用会干扰骨髓瘤细胞的诊断检测。
Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18.
6
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.基于达雷妥尤单抗的化疗后多发性骨髓瘤患者出现CD38阴性复发
Eur J Haematol. 2017 Aug;99(2):186-189. doi: 10.1111/ejh.12902. Epub 2017 Jun 6.
7
Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.复发难治性多发性骨髓瘤中CD38表达缺失
Clin Lymphoma Myeloma Leuk. 2016 May;16(5):e59-64. doi: 10.1016/j.clml.2016.02.037. Epub 2016 Feb 27.
8
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.全反式维 A 酸上调多发性骨髓瘤细胞 CD38 的表达，提高了达雷妥尤单抗的疗效。
Leukemia. 2015 Oct;29(10):2039-49. doi: 10.1038/leu.2015.123. Epub 2015 May 15.
9
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.达雷妥尤单抗，一种新型治疗性人源 CD38 单克隆抗体，可诱导多发性骨髓瘤和其他血液系统肿瘤的杀伤。
J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.
10
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.正常、反应性和恶性浆细胞的表型。“多发性骨髓瘤”的鉴定及骨髓瘤治疗新靶点
Haematologica. 2006 Sep;91(9):1234-40.